Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients

Ver/Abrir
Identificadores
URI: https://hdl.handle.net/10902/28637
ISSN: 2056-5933
Compartir
Estadísticas
Ver Estadísticas
Google Scholar
Registro completo
Mostrar el registro completo DC
Autoría
Martín Varillas, José Luis; Sánchez Bilbao, Lara; Calvo del Río, Vanesa; Adan, Alfredo M.; Hernanz, Inés; Gallego-Flores, Adela; Beltrán-Catalán, Emma; Castro-Oreiro, Sonia; Fanlo, Patricia; García Martos, Álvaro; Torre, Ignacio; Cordero-Coma, Miguel; Dios, Juan Ramón de; García-Aparicio, Ángel; Hernández-Garfella, Marisa; Sánchez-Andrade, Amalia; García-Valle, Andrea; Demetrio Pablo, Rosalía; Hernández Hernández, José LuisAutoridad Unican; [et al.]
Fecha
2022
Derechos
Attribution-NonCommercial 4.0 International
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Publicado en
RMD open 2022; 8: e002693
Editorial
BMJ Publishing Group
Enlace a la publicación
Palabras clave
Autoimmune diseases
Biological therapy
Certolizumab pegol
Systemic vasculitis
Resumen/Abstract
Objectives: To evaluate effectiveness and safety of certolizumab pegol (CZP) in uveitis due to immune-mediated inflammatory diseases (IMID). Methods: Multicentre study of CZP-treated patients with IMID uveitis refractory to conventional immunosuppressant. Effectiveness was assessed through the following ocular parameters: best-corrected visual acuity, anterior chamber cells, vitritis, macular thickness and retinal vasculitis. These variables were compared between the baseline, and first week, first, third, sixth months, first and second year. Results: We studied 80 (33 men/47 women) patients (111 affected eyes) with a mean age of 41.6±11.7 years. The IMID included were: spondyloarthritis (n=43), Behçet's disease (n=10), psoriatic arthritis (n=8), Crohn's disease (n=4), sarcoidosis (n=2), juvenile idiopathic arthritis (n=1), reactive arthritis (n=1), rheumatoid arthritis (n=1), relapsing polychondritis (n=1), CONCLUSIONS: CZP seems to be effective and safe in uveitis related to different IMID, even in patients refractory to previous biological drugs.
Colecciones a las que pertenece
Attribution-NonCommercial 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial 4.0 International